NCT01956669 · OUTCOME
Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors · Source last updated 2020-08-12
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- predose Cycle 1 Day 1, Cycle 2 Day 1
What was measured
The frequency of genetic alterations observed in participants was presented by high and low baseline plasma levels for Vascular endothelial growth factor A (VEGF-A) and Vascular endothelial growth factor receptor 1 (VEGFR-1) biomarkers. The VEGFA and VEGFR1 levels above the median were classified as high and participants with median levels or below were classified as low. Only descriptive analysis performed for participants presenting with a genetic alteration.
Analysis population: Biomarker set. Only participants with single nucleotide variant (SNV) were included in the analysis. The FLT1 gene was found to have a single SNV in one evaluable neuroblastoma participant.
Groups in this outcome
Cohort 1: Rhabdomyosarcoma (RMS)
Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS)
Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
Cohort 3: Ewing Sarcoma/pPNET (Ewing)
Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
Cohort 4 (Osteosarcoma)
Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
Cohort 5: Measurable Neuroblastoma (mNeuroblastoma)
Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
Cohort 6: Evaluable Neuroblastoma (eNeuroblastma)
Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
Cohort 7 (Hepatoblastoma)
Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 |
|---|
| Cohort 4 (Osteosarcoma) | 0 |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 1 |
|---|
| Cohort 7 (Hepatoblastoma) | 0 |
|---|
Reported measurements
VEGFA Low
Analysis denominator · Participants
| Group | Source count |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 |
|---|
| Cohort 4 (Osteosarcoma) | 0 |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 1 |
|---|
| Cohort 7 (Hepatoblastoma) | 0 |
|---|
VHL
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
FLT1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
KDR
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
HIF1A
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
KRAS
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
PIK3R1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
MAPK1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
PLCG1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
VEGFA High
Analysis denominator · Participants
| Group | Source count |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 |
|---|
| Cohort 4 (Osteosarcoma) | 0 |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 |
|---|
| Cohort 7 (Hepatoblastoma) | 0 |
|---|
VHL
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
FLT1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
KDR
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
HIF1A
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
KRAS
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
PIK3R1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
MAPK1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
PLCG1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
VEGFR1 Low
Analysis denominator · Participants
| Group | Source count |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 |
|---|
| Cohort 4 (Osteosarcoma) | 0 |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 |
|---|
| Cohort 7 (Hepatoblastoma) | 0 |
|---|
VHL
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
FLT1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
KDR
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
HIF1A
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
KRAS
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
PIK3R1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
MAPK1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
PLCG1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
VEGFR1 High
Analysis denominator · Participants
| Group | Source count |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 |
|---|
| Cohort 4 (Osteosarcoma) | 0 |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 1 |
|---|
| Cohort 7 (Hepatoblastoma) | 0 |
|---|
VHL
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
FLT1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
KDR
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
HIF1A
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
KRAS
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
PIK3R1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
MAPK1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
PLCG1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 4 (Osteosarcoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Cohort 7 (Hepatoblastoma) | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- VHL
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 1
- group Id
- OG006
- value
- 0
- title
- FLT1
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- KDR
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- HIF1A
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- KRAS
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- PIK3R1
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- MAPK1
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- PLCG1
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 1
- group Id
- OG006
- value
- 0
- units
- Participants
- title
- VEGFA Low
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- VHL
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- FLT1
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- KDR
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- HIF1A
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- KRAS
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- PIK3R1
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- MAPK1
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- PLCG1
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- units
- Participants
- title
- VEGFA High
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- VHL
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- FLT1
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- KDR
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- HIF1A
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- KRAS
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- PIK3R1
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- MAPK1
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- PLCG1
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- units
- Participants
- title
- VEGFR1 Low
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- VHL
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 1
- group Id
- OG006
- value
- 0
- title
- FLT1
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- KDR
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- HIF1A
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- KRAS
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- PIK3R1
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- MAPK1
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- title
- PLCG1
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 1
- group Id
- OG006
- value
- 0
- units
- Participants
- title
- VEGFR1 High
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 1
- group Id
- OG006
- value
- 0
- units
- Participants
- description
- The frequency of genetic alterations observed in participants was presented by high and low baseline plasma levels for Vascular endothelial growth factor A (VEGF-A) and Vascular endothelial growth factor receptor 1 (VEGFR-1) biomarkers. The VEGFA and VEGFR1 levels above the median were classified as high and participants with median levels or below were classified as low. Only descriptive analysis performed for participants presenting with a genetic alteration.
- groups
- description
- Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
- id
- OG000
- title
- Cohort 1: Rhabdomyosarcoma (RMS)
- description
- Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
- id
- OG001
- title
- Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS)
- description
- Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
- id
- OG002
- title
- Cohort 3: Ewing Sarcoma/pPNET (Ewing)
- description
- Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
- id
- OG003
- title
- Cohort 4 (Osteosarcoma)
- description
- Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
- id
- OG004
- title
- Cohort 5: Measurable Neuroblastoma (mNeuroblastoma)
- description
- Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
- id
- OG005
- title
- Cohort 6: Evaluable Neuroblastoma (eNeuroblastma)
- description
- Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
- id
- OG006
- title
- Cohort 7 (Hepatoblastoma)
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Biomarker set. Only participants with single nucleotide variant (SNV) were included in the analysis. The FLT1 gene was found to have a single SNV in one evaluable neuroblastoma participant.
- reporting Status
- POSTED
- time Frame
- predose Cycle 1 Day 1, Cycle 2 Day 1
- title
- Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle